AC Immune posted an IFRS net loss of CHF 12.9 million, narrowing from CHF 40.2 million a year earlier.
Revenue climbed to CHF 16.2 million from CHF 2.3 million, driven by CHF 11 million recognized under Lilly milestones and CHF 5.2 million under Takeda work.
R&D expenses fell to CHF 22.2 million from CHF 32.7 million; G&A costs eased to CHF 7.7 million from CHF 8.3 million.
Cash position and development updates
Cash resources totaled CHF 75.4 million at June 30, funding operations into Q4 2027, excluding potential milestone payments.
Takeda triggered a $12 million milestone on ABATE AD4 cohort start; VacSYn Phase 2 Part 1 week-104 data are expected in H2 2026.
ACIU•
